Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elevated diurnal CD36 expression disrupts the bile acid synthesis rhythm leading to cholestatic liver injury and inflammation via the HMGCR/CYP7A1 axis.

Genes & diseases·2026
Same author

Ligand-Activated Fluorescent Probe Reveals Mitochondrial Long-Chain Saturated Fatty Acid Flux: An Effective Tool for Metabolic Disorder Studies.

Small methods·2026
Same author

Hypoxia-responsive modules via tunable hydrophobicity reversal enhance renal-targeted release of CD36-interfering nanoparticles to ameliorate acute kidney injury.

Journal of controlled release : official journal of the Controlled Release Society·2025
Same author

Dietary monounsaturated fatty acid facilitates lipid droplet turnover through chaperone HSP90A-mediated lysosomal degradation of PLIN2 in hepatocellular carcinoma.

Autophagy·2025
Same author

The X-Age Project to construct a Chinese aging clock.

Nature aging·2025
Same author

SCAP Interacts with Trim27 to Promote Vascular Neointimal Hyperplasia by Regulating the Stability and Ubiquitination of IκBα.

Aging and disease·2025
Same journal

KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

Kidney international·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

Kidney international·2026
Same journal

Crystal-storing histiocytosis causing severe acute kidney injury.

Kidney international·2026
Same journal

Peritoneal dialysis in a patient with extensive burn scarring.

Kidney international·2026
Same journal

COPA syndrome unmasked by anti-neutrophil cytoplasmic antibody-positive immune-complex nephritis.

Kidney international·2026
Same journal

Monitoring anti-nephrin antibodies in the management of recurrent diffuse podocytopathy.

Kidney international·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Mouse Model of Acute to Chronic Kidney Disease Transition Induced by Renal Ischemia/Reperfusion Injury
07:02

Mouse Model of Acute to Chronic Kidney Disease Transition Induced by Renal Ischemia/Reperfusion Injury

Published on: February 10, 2026

Lipid redistribution in renal dysfunction.

Xiong Z Ruan1, John F Moorhead, Zac Varghese

  • 1Centre for Nephrology, Royal Free and University College Medical School, University College London, Royal Free Campus, London, United Kingdom. x.ruan@medsch.ucl.ac.uk

Kidney International
|August 2, 2008
PubMed
Summary
This summary is machine-generated.

Chronic renal failure involves lipid redistribution in organs, potentially explaining lipid-related kidney and vascular injury. Targeting lipid redistribution may offer new therapeutic strategies for kidney disease.

Related Experiment Videos

Last Updated: Jul 3, 2026

Mouse Model of Acute to Chronic Kidney Disease Transition Induced by Renal Ischemia/Reperfusion Injury
07:02

Mouse Model of Acute to Chronic Kidney Disease Transition Induced by Renal Ischemia/Reperfusion Injury

Published on: February 10, 2026

Area of Science:

  • Nephrology
  • Cardiovascular Science
  • Metabolic Research

Background:

  • Chronic renal failure is linked to altered lipid distribution within the kidneys and other organs, as shown by Zhao et al.
  • Lipid redistribution plays a role in various physiological and pathological processes.

Discussion:

  • This review explores three types of lipid redistribution, particularly in the context of inflammatory stress.
  • Understanding these mechanisms may resolve conflicting clinical findings regarding lipid-mediated renal and vascular damage.

Key Insights:

  • Lipid redistribution is a significant factor in chronic renal failure.
  • Inflammatory stress modulates lipid redistribution, impacting organ injury.
  • Conflicting clinical observations in lipid-mediated injury may be explained by lipid redistribution patterns.

Outlook:

  • Assessing lipid redistribution offers a novel therapeutic target for kidney disease.
  • Further research into lipid redistribution could lead to improved treatments for renal and vascular complications.